218 related articles for article (PubMed ID: 31877673)
1. Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.
Festuccia C; Mancini A; Gravina GL; Colapietro A; Vetuschi A; Pompili S; Ventura L; Delle Monache S; Iorio R; Del Fattore A; Fogler W; Magnani J
Cells; 2019 Dec; 9(1):. PubMed ID: 31877673
[TBL] [Abstract][Full Text] [Related]
2. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
3. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
[TBL] [Abstract][Full Text] [Related]
4. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
[TBL] [Abstract][Full Text] [Related]
5. Mifepristone Has Limited Activity to Enhance the
Yang Y; Li X; Mamouni K; Kucuk O; Wu D
Anticancer Res; 2017 Nov; 37(11):6235-6243. PubMed ID: 29061806
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.
Hoang B; Ernsting MJ; Murakami M; Undzys E; Li SD
Int J Pharm; 2014 Aug; 471(1-2):224-33. PubMed ID: 24853460
[TBL] [Abstract][Full Text] [Related]
7. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
8. Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression.
Hu L; Sun Y; Luo J; He X; Ye M; Li G; Zhang Y; Bai J; Zhang D; Chang C
Oncogene; 2020 Feb; 39(9):1891-1903. PubMed ID: 31748715
[TBL] [Abstract][Full Text] [Related]
9. SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer.
Chen J; Wu Z; Ding W; Xiao C; Zhang Y; Gao S; Gao Y; Cai W
Theranostics; 2020; 10(4):1619-1632. PubMed ID: 32042326
[TBL] [Abstract][Full Text] [Related]
10. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
[TBL] [Abstract][Full Text] [Related]
11. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer.
Huang EH; Singh B; Cristofanilli M; Gelovani J; Wei C; Vincent L; Cook KR; Lucci A
J Surg Res; 2009 Aug; 155(2):231-6. PubMed ID: 19482312
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancer.
Zhu S; Oremo JA; Li S; Zhen M; Tang Y; Du Y
PLoS One; 2014; 9(3):e91817. PubMed ID: 24632829
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Associated Macrophage Promotes the Survival of Cancer Cells upon Docetaxel Chemotherapy via the CSF1/CSF1R-CXCL12/CXCR4 Axis in Castration-Resistant Prostate Cancer.
Guan W; Li F; Zhao Z; Zhang Z; Hu J; Zhang Y
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34069563
[TBL] [Abstract][Full Text] [Related]
15. A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis.
Robinson T; Escara-Wilke J; Dai J; Zimmermann J; Keller ET
Prostate; 2023 Sep; 83(13):1247-1254. PubMed ID: 37244751
[TBL] [Abstract][Full Text] [Related]
16. Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer.
Hoang B; Ernsting MJ; Tang WS; Bteich J; Undzys E; Kiyota T; Li SD
Cancer Lett; 2017 Dec; 410():169-179. PubMed ID: 28965854
[TBL] [Abstract][Full Text] [Related]
17. Glyceryl trinitrate‑induced cytotoxicity of docetaxel‑resistant prostatic cancer cells is associated with differential regulation of clusterin.
Bouaouiche S; Magadoux L; Dondaine L; Reveneau S; Isambert N; Bettaieb A; Jeannin JF; Laurens V; Plenchette S
Int J Oncol; 2019 Apr; 54(4):1446-1456. PubMed ID: 30720069
[TBL] [Abstract][Full Text] [Related]
18. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model.
Hassan S; Buchanan M; Jahan K; Aguilar-Mahecha A; Gaboury L; Muller WJ; Alsawafi Y; Mourskaia AA; Siegel PM; Salvucci O; Basik M
Int J Cancer; 2011 Jul; 129(1):225-32. PubMed ID: 20830712
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.
Zhang S; Gera L; Mamouni K; Li X; Chen Z; Kucuk O; Wu D
Oncotarget; 2016 May; 7(19):27489-98. PubMed ID: 27050371
[TBL] [Abstract][Full Text] [Related]
20. Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer.
Zhang B; Li Y; Wu Q; Xie L; Barwick B; Fu C; Li X; Wu D; Xia S; Chen J; Qian WP; Yang L; Osunkoya AO; Boise L; Vertino PM; Zhao Y; Li M; Chen HR; Kowalski J; Kucuk O; Zhou W; Dong JT
Nat Commun; 2021 Mar; 12(1):1714. PubMed ID: 33731701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]